Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(23):1711; doi:10.1093/jnci/dji451
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Dose-Dense Chemotherapy in Early Breast Cancer

To determine whether a dose-dense chemotherapy regimen could improve outcomes in patients with early breast cancer, Venturini et al. (p. 1724) compared outcomes with the same regimen of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) given every 3 weeks (FEC21) or every 2 weeks (FEC14) in a phase III randomized trial. (Patients on FEC14 also received a granulocyte colony-stimulating factor.) After a median follow-up of 10.4 years, they found no statistically significant difference in the hazard of death or recurrence between arms. They reported that acute toxicity associated with either treatment was mild and easy . . . [Full Text of this Article]

Smad7 Expression and Metastasis Inhibition

Mechanism of Estradiol-Induced Apoptosis

Chronic Stress and Risk of Skin Cancer

Dairy and Calcium Intakes and Prostate Cancer Risk

Tlr4 in Chronic Lung Inflammation and Tumorigenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?